CRISPR/Cas9 Technology Targeting Fas Gene Protects Mice From Concanavalin‐A Induced Fulminant Hepatic Failure

• Published in: Journal of cellular biochemistry Vol. 118; no. 3; pp. 530 - 536
• Main Authors: Liang, Wei‐Cheng, Liang, Pu‐Ping, Wong, Cheuk‐Wa, Ng, Tzi‐Bun, Huang, Jun‐Jiu, Zhang, Jin‐Fang, Waye, Mary Miu‐Yee, Fu, Wei‐Ming
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.03.2017
• Subjects: Animals; Apoptosis - genetics; Cell Line; Clustered Regularly Interspaced Short Palindromic Repeats; Concanavalin A - toxicity; CRISPR/Cas9; Disease Models, Animal; Fas GENE; fas Receptor - genetics; fas Receptor - metabolism; FULMINANT HEPATIC FAILURE; Gene Targeting; GENE THERAPY; Hepatocytes - metabolism; Liver Failure, Acute - chemically induced; Liver Failure, Acute - genetics; Liver Failure, Acute - metabolism; Liver Failure, Acute - prevention & control; Mice; Mice, Inbred ICR; FULMINANT HEPATIC FAILURE; GENE THERAPY; CRISPR/Cas9; Fas GENE

ABSTRACT Fulminant hepatic failure is a life‐threatening disease which occurs in patients without preexisting liver disease. Nowadays, there is no ideal therapeutic tool in the treatment of fulminant hepatic failure. Recent studies suggested that a novel technology termed CRISPR/Cas9 may be a promis...